JP2022549186A5 - - Google Patents
Info
- Publication number
- JP2022549186A5 JP2022549186A5 JP2022517731A JP2022517731A JP2022549186A5 JP 2022549186 A5 JP2022549186 A5 JP 2022549186A5 JP 2022517731 A JP2022517731 A JP 2022517731A JP 2022517731 A JP2022517731 A JP 2022517731A JP 2022549186 A5 JP2022549186 A5 JP 2022549186A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding
- amino acid
- binding molecule
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902915P | 2019-09-19 | 2019-09-19 | |
| US62/902,915 | 2019-09-19 | ||
| PCT/US2020/051513 WO2021055765A2 (en) | 2019-09-19 | 2020-09-18 | Multimeric antibodies with enhanced selectivity for cells with high target density |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549186A JP2022549186A (ja) | 2022-11-24 |
| JP2022549186A5 true JP2022549186A5 (https=) | 2023-08-28 |
Family
ID=74884716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517731A Pending JP2022549186A (ja) | 2019-09-19 | 2020-09-18 | 高い標的密度の細胞に対する選択性を向上させた多量体抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220372142A1 (https=) |
| EP (1) | EP4031252A4 (https=) |
| JP (1) | JP2022549186A (https=) |
| CN (1) | CN114616031A (https=) |
| AU (1) | AU2020351205A1 (https=) |
| CA (1) | CA3151237A1 (https=) |
| IL (1) | IL291340A (https=) |
| WO (1) | WO2021055765A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2022212191A1 (en) * | 2021-04-01 | 2022-10-06 | Modernatx, Inc. | Mucosal expression of antibody structures and isotypes by mrna |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| PL3560954T3 (pl) * | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| EP3957738A1 (en) * | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| EP3356401B1 (en) * | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| CA3035427A1 (en) * | 2016-09-01 | 2018-03-08 | Umc Utrecht Holding B.V. | Cd20 antibodies |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| MX2020009069A (es) * | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
-
2020
- 2020-09-18 AU AU2020351205A patent/AU2020351205A1/en not_active Abandoned
- 2020-09-18 CN CN202080073088.3A patent/CN114616031A/zh active Pending
- 2020-09-18 EP EP20865145.5A patent/EP4031252A4/en not_active Withdrawn
- 2020-09-18 CA CA3151237A patent/CA3151237A1/en active Pending
- 2020-09-18 WO PCT/US2020/051513 patent/WO2021055765A2/en not_active Ceased
- 2020-09-18 JP JP2022517731A patent/JP2022549186A/ja active Pending
- 2020-09-18 US US17/761,428 patent/US20220372142A1/en not_active Abandoned
-
2022
- 2022-03-14 IL IL291340A patent/IL291340A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022549186A5 (https=) | ||
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP7701197B2 (ja) | 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| CA2920117C (en) | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof | |
| US20220372142A1 (en) | Multimeric antibodies with enhanced selectivity for cells with high target density | |
| US20220242953A1 (en) | Cd3 antibody and pharmaceutical use thereof | |
| JP2021520805A (ja) | ４−１ＢＢＬを含むＨｅｒ２標的化抗原結合分子 | |
| JP7611931B2 (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| CA3087488A1 (en) | Edb targeting il-12 compositions | |
| JP2022545655A5 (https=) | ||
| KR20230141817A (ko) | 이중특이 항체 | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| CN116496404A (zh) | 靶向cd47和pd-l1的双特异性抗体及其应用 | |
| JP2025506341A5 (https=) | ||
| CN120530135A (zh) | 抗b7h3抗体和使用方法 | |
| TW202544039A (zh) | 對ｃｄ４７和ｐｄｌ１具有特異性的多特異性抗體、編碼其之核酸、包含其之醫藥組合物、對應其之抗體結合域、包含對應其之抗體結合域之抗體及包含編碼其之核酸的宿主細胞 | |
| WO2025092742A1 (zh) | 结合bcma的抗体以及包含其的多特异性抗体 | |
| HK40129137A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| HK40073540A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| HK40073540B (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 |